Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
Publication
, Journal Article
Curtis, JR; Martin, C; Saag, KG; Patkar, NM; Kramer, J; Shatin, D; Allison, J; Braun, MM
Published in: Arthritis Rheum
March 15, 2007
Duke Scholars
Published In
Arthritis Rheum
DOI
ISSN
0004-3591
Publication Date
March 15, 2007
Volume
57
Issue
2
Start / End Page
343 / 346
Location
United States
Related Subject Headings
- Tumor Necrosis Factor-alpha
- Receptors, Tumor Necrosis Factor
- Predictive Value of Tests
- Opportunistic Infections
- Middle Aged
- Male
- Insurance, Health
- Infliximab
- Incidence
- Immunoglobulin G
Citation
APA
Chicago
ICMJE
MLA
NLM
Curtis, J. R., Martin, C., Saag, K. G., Patkar, N. M., Kramer, J., Shatin, D., … Braun, M. M. (2007). Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum, 57(2), 343–346. https://doi.org/10.1002/art.22544
Curtis, J. R., C. Martin, K. G. Saag, N. M. Patkar, J. Kramer, D. Shatin, J. Allison, and M. M. Braun. “Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.” Arthritis Rheum 57, no. 2 (March 15, 2007): 343–46. https://doi.org/10.1002/art.22544.
Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, et al. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum. 2007 Mar 15;57(2):343–6.
Curtis, J. R., et al. “Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.” Arthritis Rheum, vol. 57, no. 2, Mar. 2007, pp. 343–46. Pubmed, doi:10.1002/art.22544.
Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, Allison J, Braun MM. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum. 2007 Mar 15;57(2):343–346.
Published In
Arthritis Rheum
DOI
ISSN
0004-3591
Publication Date
March 15, 2007
Volume
57
Issue
2
Start / End Page
343 / 346
Location
United States
Related Subject Headings
- Tumor Necrosis Factor-alpha
- Receptors, Tumor Necrosis Factor
- Predictive Value of Tests
- Opportunistic Infections
- Middle Aged
- Male
- Insurance, Health
- Infliximab
- Incidence
- Immunoglobulin G